Xtrava develops a versatile lateral flow reader that integrates with a cloud platform and mobile app for real-time tracking and analysis of pandemic spread. Their technology provides accurate at-home testing with enhanced sensitivity, ensuring reliable results while simplifying the testing process for users, including those with accessibility needs.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional lateral flow tests often lack sensitivity and require subjective visual interpretation, leading to inaccurate results and hindering effective tracking of disease spread. Current testing methods can be difficult for individuals with visual impairments or limited dexterity, further complicating the testing process.
Solution
Xtrava Health offers a digital lateral flow reader that enhances the accuracy and accessibility of rapid diagnostic testing. The system consists of a portable reader, a mobile application, and a cloud platform for real-time data analysis and tracking. The reader improves strip sensitivity, reduces false positives, and allows for the detection of multiple pathogens simultaneously. A fully autonomous, app-free version is also available, featuring audible instructions and automated analysis, making it suitable for users with visual impairments or those who prefer a simplified testing experience. The cloud platform enables real-time tracking of test results, generation of heat maps, and customizable reporting for pandemic preparedness and other applications.
Target Audience
The primary target audience includes public health organizations, healthcare providers, and individuals seeking accurate and accessible at-home testing solutions for pandemic preparedness and other diagnostic applications.
Features
- Portable digital reader for accurate and objective interpretation of lateral flow tests
- Enhanced strip sensitivity, reducing false positives and improving detection limits
- Capability to detect up to three pathogens simultaneously
- App-enabled version for general use with an intuitive mobile interface
- Fully autonomous, app-free version with audible instructions for users with accessibility needs
- Cloud platform for real-time tracking, analysis, and reporting of test results
- Customizable cross-reactivity thresholds to enhance test specificity
- Easy-to-use cassette design to improve overall test performance